US › Healthcare

Precision BioSciences Inc (DTIL)

US · Healthcare · Biotechnology

$10.60+7.40%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit

$-7.6M

EPS

$-0.65

EPS estimate

$-1.02

EPS came in at -0.65 against a street estimate of -1.02 — a beat of 36.3%.

Key statistics

Market cap

$226.8M

P/E

28.0

Forward P/E

11.8

P/B

4.25

Book value

$3.83

EPS (TTM)

$0.29

52-week high

$9.62

52-week low

$3.53

50-day MA

$6.83

200-day MA

$6.57

Beta

1.35

Analyst view

Analysts rate Precision BioSciences Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $29.40.

Shareholding

Insiders

8.04%

Institutions

67.99%

Largest institutional holders

Fund	Stake
Aberdeen Group PLC	8.08%
Bleichroeder LP	7.31%
Octagon Capital Advisors LP	4.89%
BOOTHBAY FUND MANAGEMENT, LLC	4.88%
BlackRock Inc	4.25%
Vanguard Capital Management, LLC	4.04%
Lynx1 Capital Management, LP	3.44%
Driehaus Capital Management LLC	3.43%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Precision BioSciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.